Expression and purification of exendin-4, a GLP-1 receptor agonist, in Escherichia coli

Protein Expression and Purification

Volumn 41, Issue 2, 2005, Pages 259-265

  Yin, Xiaopu ^a   Wei, Dongzhi ^a   Yi, Lina ^a   Tao, Xinyi ^a   Ma, Yushu ^a  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Exendin 4; Expression; Glucose lowering action

Indexed keywords

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; GILA; HELODERMA SUSPECTUM;

EID: 18144403837     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2004.10.014     Document Type: Article

References (32)

1. U. Ritzel, A. Fromme, M. Ottleben, U. Leonhardt, and G. Ramadori Release of glucagon-like peptide-1 (GLP-1) by carbohydrates in the perfused rat ileum Acta Diabetol. 34 1997 18 21
2. A.S. Rocca, and P.L. Brubaker Stereospecific effects of fatty acids on proglucagon-derived peptide secretion in fetal rat intestinal cultures Endocrinology 136 1995 5593 5599
3. R.M. Elliott, L.M. Morgan, J.A. Tredger, S. Deacon, J. Wright, and V. Marks Glucagon-like peptide-1 (7-36) amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns J. Endocrinol. 138 1993 159 166
4. M. Cordier-Bussat, C. Bernard, F. Levenez, N. Klages, B. Laser-Ritz, J. Philippe, J.A. Chayvialle, and J.C. Cuber Peptones stimulate both the secretion of the incretin hormone glucagon-like peptide 1 and the transcription of the proglucagon gene Diabetes 47 1998 1038 1045
5. B. Kreymann, G. Williams, M.A. Ghatei, and S.R. Bloom Glucagon-like peptide-1 7-36: a physiological incretin in man Lancet 2 1987 1300 1304
6. M.A. Nauck, U. Niedereichholz, R. Ettler, J.J. Holst, C. Orskov, R. Ritzel, and W.H. Schmiegel Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans Am. J. Physiol. 273 1997 E981 E988
7. L.B. Knudsen, P.F. Nielsen, P.O. Huusfeldt, S.L. Johansen, K. Madsen, F.Z. Pedersen, H. Thøgersen, M. Wilken, and H. Agersø Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration J. Med. Chem. 43 2000 1664 1669
8. A. Wettergren, B. Schjoldager, P.E. Mortensen, J. Myhre, J. Christiansen, and J.J. Holst Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man Dig. Dis. Sci. 38 1993 665 673
9. D.A. D'Alessio, S.E. Kahn, C.R. Leusner, and J.W. Ensinck Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal J. Clin. Invest. 93 1994 2263 2266
10. M. Gutniak, C. Ørskov, J.J. Holst, B. Ahren, and S. Efendic Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus N. Engl. J. Med. 326 1992 1316 1322
11. L. Ørskov, J.J. Holst, J. Møller, C. Ørskov, N. Møller, K.G.M.M. Alberti, and O. Schmitz GLP-1 does not acutely affect insulin sensitivity in healthy man Diabetologia 39 1996 1227 1232
12. A. Flint, A. Raben, A. Astrup, and J.J. Holst Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans J. Clin. Invest. 101 1998 515 520
13. J.P. Gutzwiller, B. Goke, J. Drewe, P. Hildebrand, S. Ketterer, D. Handschin, R. Winterhalder, D. Conen, and C. Beglinger Glucagon-like peptide-1: a potent regulator of food intake in humans Gut 44 1999 81 86
14. S.J. Long, J.A. Sutton, W.B. Amaee, A. Giouvanoudi, N.M. Spyrou, P.J. Rogers, and L.V. Morgan No effect of glucagon-like peptide-1 on short-term satiety and energy intake in man Br. J. Nutr. 81 1999 273 279
15. E. Naslund, B. Barkeling, N. King, M. Gutniak, J.E. Blundell, J.J. Holst, S. Rossner, and P.M. Hellstrom Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men Int. J. Obes. 23 1999 304 311
16. J. Zhou, X.L. Wang, M.A. Pineyro, and J.M. Egan Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells Diabetes 48 1999 2358 2366
17. G. Xu, D.A. Stoffers, J.F. Habener, and S.B. Weir Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats Diabetes 48 1999 2270 2276
18. J. Gromada, J.J. Holst, and P. Rorsman Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1 Pflugers Arch. 435 1998 583 594
19. M.B. Wheeler, M. Lu, J.S. Dillon, X.H. Leng, C. Chen, and A.E. Boyd III Functional expression of the rat glucagon-like peptide-I receptor, evidence for coupling to both adenylyl cyclase and phospholipase-C Endocrinology 133 1993 57 62
20. M. Frodin, N. Sekine, E. Roche, C. Filloux, M. Prentki, C.B. Wollheim, and E. Van Obberghen Glucose, other secretagogues, and nerve growth factor stimulate mitogen-activated protein kinase in the insulin-secreting cell line INS-1 J. Biol. Chem. 270 1995 7882 7889
21. Y. Kashima, T. Miki, T. Shibasaki, N. Ozaki, M. Miyazaki, H. Yano, and S. Seino Critical role of cAMP-GEFII-Rim2 complex in incretin-potentiated insulin secretion J. Biol. Chem. 276 2001 46046 46053
22. 2+ release in INS-1 pancreatic cells J. Physiol. 536 2001 375 385
23. C.F. Deacon, A.H. Johnsen, and J.J. Holst Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo J. Clin. Endocrinol. Metab. 80 1995 952 957
24. A. Wettergren, M. Wøjdemann, and J.J. Holst Glucagon-like peptide-1 (7-36) amide's inhibitory effect on antral motility is antagonised by its N-terminally truncated gon-like peptide 1 (9-36) amide Peptides 19 1998 877 882
25. J.J. Holst, and C.F. Deacon Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes Diabetes 47 1998 1663 1670
26. N.H. Greig, H.W. Holloway, K.A. De Ore, D. Jani, Y. Wang, J. Zhou, M.J. Garant, and J.M. Egan Once daily injections of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations Diabetologia 42 1999 45 50
27. M. Szayna, M.E. Doyle, J.A. Betkey, H.W. Holloway, R.G. Spencer, N.H. Greig, and J.M. Egan Exendin-4 decelerates food intake, weight gain and fat deposition in Zucker rats Endocrinology 141 2000 1936 1941
28. A.A. Young, B.R. Gedulin, S. Bhavsar, N. Bodkin, C. Jodka, B. Hansen, and M. Denaro Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta) Diabetes 48 1999 1026 1034
29. J. Sambrook, D.W. Russell, Molecular Cloning: A Laboratory Manual, third ed., 2001, pp. 1595-1597
30. J. Sambrook, D.W. Russell, Molecular Cloning: A Laboratory Manual, third ed., 2001, pp. 1474-1481
31. 2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity Diabetes 48 1999 758 765
32. Z.Z. Zhang, S.S. Yang, and J.F. Mao Expression, purification and bioactivity of recombinant GLP-1 J. Biochem. Mol. Biol. (China) 18 2002 5 8